Edition:
United States

Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

1,050.00USD
--
Change (% chg)

-- (--)
Prev Close
$1,050.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
17
52-wk High
$1,100.00
52-wk Low
$788.70

Chart for

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.18
Market Cap(Mil.): $103,905.70
Shares Outstanding(Mil.): 1,639.93
Dividend: 0.39
Yield (%): 2.46

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

BRIEF-AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors

* AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors

Sep 22 2017

BRIEF-Japanese ministry of Health, Labor and Welfare approves Opdivo for treatment of unresectable advanced or recurrent gastric cancer

* Bristol-Myers Squibb - Japanese Ministry of Health, Labor and Welfare has approved Opdivo for treatment of unresectable advanced or recurrent gastric cancer Source text for Eikon: Further company coverage:

Sep 22 2017

UK backs Opdivo for lung cancer after Bristol-Myers cuts price

LONDON Bristol-Myers Squibb's immunotherapy drug Opdivo has been recommended for some patients with lung cancer by Britain's healthcare cost watchdog NICE after the drugmaker agreed a discounted price.

Sep 19 2017

UK backs Opdivo for lung cancer after Bristol-Myers cuts price

LONDON, Sept 20 Bristol-Myers Squibb's immunotherapy drug Opdivo has been recommended for some patients with lung cancer by Britain's healthcare cost watchdog NICE after the drugmaker agreed a discounted price.

Sep 19 2017

Halozyme to license drug delivery tech to Roche, Bristol-Myers

U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations.

Sep 14 2017

Halozyme to license drug delivery tech to Roche, Bristol-Myers

Sept 14 U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations.

Sep 14 2017

BRIEF-Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology

* Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology

Sep 14 2017

Bristol-Myers urges Abilify MDL court to compel plaintiff discovery

Bristol-Myers Squibb has asked a federal court to compel four plaintiffs, their families and physicians to provide more documents relating to their claims that the anti-psychotic drug Abilify caused them to develop severe gambling addictions and other compulsive behavior.

Sep 13 2017

BRIEF-Bristol-Myers Squibb says Karen Vousden elected as member of board

* Bristol-Myers Squibb Co - ‍on Sept 13, board elected Karen Vousden to serve as member of board; size of board was increased to eleven - SEC filing​ Source text: [http://bit.ly/2x04hcV] Further company coverage:

Sep 13 2017

BRIEF-Bristol-Myers Squibb Co says ‍declared a quarterly dividend

* Bristol-Myers Squibb Co - ‍declared a quarterly dividend of thirty-nine cents ($0.39) per share on $.10 par value common stock of corporation​ Source text for Eikon: Further company coverage:

Sep 13 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $131.39 -0.36
Pfizer Inc. (PFE.N) $35.96 -0.01
Merck & Co., Inc. (MRK.N) $65.13 -0.47
Sanofi SA (SASY.PA) €84.12 +0.25
AstraZeneca plc (AZN.L) 4,912.00 +143.50
GlaxoSmithKline plc (GSK.L) 1,474.00 +6.00
Eli Lilly and Co (LLY.N) $83.91 +0.58
Roche Holding Ltd. (ROG.S) CHF248.00 -1.00
Roche Holding Ltd. (RO.S) CHF248.00 -1.00

Earnings vs. Estimates